The overall cohort of anti-MPO-positive ILD patients had a better 52-week survival in comparison with 116 age-matched reference IPF cases (71.4 ± 7.5% vs. 52.4 ± 5.9% for anti-MPO-positive ILD patients and IPF, respectively; p = 0.045). This evidence concerns the gene MPO and interstitial lung disease.